drugset
drugset / Trial / NCT05476965

Selected De-escalation Radiotherapy for Postoperative Head and Neck Squamous Cell Carcinoma

NCT05476965 ↗

Phase 2 Unknown 20 enrolled Hubei Cancer Hospital
Non-randomizedParallel-groupDouble-blindTreatment

Summary

This study is looking to see if sintilimab, an anti-PD-1 McAb given with cisplatinum and paclitaxel (2 chemotherapy agents) during induction therapy in advanced head and neck squamous cell carcinoma can significantly shrink the subject's cancer, then de-escalation radiotherapy can be used.

Timeline

Start
2021-01-01
Primary completion
2022-12
Completion
2024-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified — —
Subject Paclitaxel Small molecule — —
Subject Sintilimab Monoclonal antibody — —

Indications

head and neck squamous cell carcinoma